Leading the Way in Life Science Technologies

GEN Exclusives

More »

Columns

More »
Sep 15, 2009 (Vol. 29, No. 16)

Parvovirus B19 VLP Vaccine Manufacturing

Meridian Developed Production Process for Technology Licensed from NHLBI

  • Conclusions

    Multiple groups are at risk of potentially life-threatening complications due to human parvovirus B19 infection. Based on the infectious nature of HPVB19 infection in children and the severe potential consequence of transplacental fetal infection, a two-pronged vaccination strategy to manage HPVB19 infections in these populations is recommended.

    First, incorporation of a HPVB19 vaccine into the early childhood vaccination schedule could reduce the overall incidence of this virus in the population. Second, a safe vaccine that can elicit protective neutralizing antibodies could be provided to women of childbearing age as prophylactic care to reduce the overall incidence of transplacental fetal infection.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »